INTRODUCTION
Binding of antibody to surface antigens and fixation of complement to the surfaces of cells are two of a variety of mechanisms that mediate immunologic injury to cells of patients with immune hemolytic anemia and immune thrombocytopenia (1) . The role of im-munoglobulin-mediated complement activation in cell destruction is well understood in warm antibody autoimmune hemolytic anemia (2) , cold agglutinin hemolysis (2, 3) , and quinidine purpura (4) . Despite the apparent clinical analogy of immune granulocytopenia to immune hemolytic anemia and immune thrombocytopenia, immunologic mechanisms directed against granulocytes are not well defined in immune granulocytopenia. Specifically, the ability of antigranulocyte antibody to activate and fix human complement to granulocytes has not been explored.
Although cell-mediated immunity appears to be involved in some patients with autoimmune granulocytopenia (5, 6) , we and others have demonstrated that patients with Felty's syndrome (FS)' often have increased serum granulocyte-binding IgG (7) (8) (9) (10) (11) . By analogy with immune hemolytic anemia and immune thrombocytopenia, one might expect some FS sera to bind complement to granulocytes. Membrane-bound components of complement may modulate the host's interaction with its own granulocytes by involving cells with receptors for those components (12) . The ability of antigranulocyte antibodies to fix complement to granulocytes may have implications for the type and subclass of immunoglobulin involved in granulocyte destruction, in addition to providing information about the arrangement of granulocyte surface antigens. Consequently, we sought to determine whether antibodies in the sera of patients with FS fixed complement to granulocytes.
In this study, we describe an assay system to detect and quantitate the third component of human com-plement (C3) on the granulocyte surface and provide evidence for the ability of serum from patients with FS to activate complement and fix C3 to allogeneic granulocytes. Most FS sera were able to fix greater amounts of CS to granulocytes than sera from patients with uncomplicated rheumatoid arthritis (RA), and this ability appeared to reside in the monomeric IgGcontaining fraction of FS serum. For the majority of patients, the amount of C3 fixed was directly related to the amount of granulocyte-binding IgG present.
METHODS
Patients. Sera from 13 patients with classic FS were examined. The group consisted of nine males and four females. There was no history of blood transfusion in 9 of the 13 patients. Two patients, both males, had undergone splenectomy, and one of them had responded with normalization of his granulocyte count. Both of these patients had been transfused preoperatively and serum for testing was obtained 5 yr after transfusion. Two other male patients had been transfused 4 and 2 yr before testing. All four females were over 55 yr of age and one was multiparous. All patients except one were granulocytopenic (granulocyte count < 1000/cm3) at the time of study.
Sera and complement sources. Control sera from normal volunteers and patients without RA or immune granulocytopenia, and test sera from patients with uncomplicated RA and patients with FS were obtained from peripheral venous blood that had been allowed to clot at room temperature. Following centrifugation at 800 g, the sera were stored at -50°C for up to 12 mo. Sera were obtained from healthy volunteers for use in the fresh state as a source of complement. Immediately before use, thawed test sera and fresh sera were centrifuged for 1.5 min in a Beckman Microfuge B miniature centrifuge (Beckman Instruments, Inc., Palo Alto, CA) and then diluted with veronal-buffered isotonic saline pH 7.4 with 0.15 mM calcium chloride and 0.50 mM magnesium chloride (VBS) (13) .
Granulocytes. Peripheral venous blood from 0 blood type normal male volunteers and from one splenectomized nongranulocytopenic patient with FS was drawn into heparinized syringes. Granulocytes were harvested by sedimentation of blood at 1 g in 20% (vol/vol) Plasmagel (H.T.I. Corporation, Buffalo, NY) for 45 min at room temperature followed by 400,000-mol wt Ficoll-sodium diatrizoate (Sigma Chemical Co., St. Louis, MO) discontinuous density gradient (specific gravities 1.119 and 1.077) centrifugation of the leukocyte-rich plasma for 20 min at 800 g (10, 14) . The granulocyte layer was removed, washed once in Alsever's solution (13) to minimize autoagglutination, resuspended, and treated with 1 vol 2% (wt/vol) paraformaldehyde (Fisher Scientific Co., Pittsburgh, PA) in phosphate-buffered saline pH 7.2 for 10 min at room temperature (8, 15) . These paraformaldehyde-fixed granulocytes (PFG) were then washed twice and resuspended in Alsever's solution before storage at -50°C for up to 3 mo. Immediately before use, PFG were thawed, washed in VBS, and adjusted to a concentration of 20 million cells/ml. All cell washing procedures were done by centrifugation at 800 g for 10 Fig. 3 . Increasing concentrations of fresh sera in the initial reaction mixture resulted in increasing amounts of anti-C3 bound by cells exposed to both patient and normal control sera. A 1:10 dilution of fresh normal serum appeared to be an adequate source of complement in the standard assay.
To determine the time course of C3 fixation to the cell surface by FS serum, granulocytes were incubated with serum from a patient with FS in the presence of a source of complement for varying time intervals and then assayed for anti-C3 binding, using the standard assay. The results are illustrated in Fig. 4 . Both FS and normal control sera led to increased binding of anti-CS with longer periods of incubation 1. Anti-C3 bound by control sera increased linearly after 15 min, but the maximal difference between FS and contol sera occurred after 45 min. This incubation period was used in subsequent experiments.
Variation of conditions in incubation 2. A 20-min period was found to be the optimum duration of incubation of anti-C3 with reacted cells. When increasing amounts of anti-C3 were added to reacted cells in incubation 2, 100 ng appeared to be adequate to detect differences in C3 fixation to PFG by FS and control sera (Fig. 5) Fig. 1 . A minimal amount of binding occurred at 4°C and slightly more at 22.5°C. 67.5 fg were bound by cells incubated with FS serum and complement at 37°C.
The effect of complement inactivation on the amount of anti-C3 binding was determined ( Table I) . Use of heated normal serum as a source of complement for both FS and control sera in incubation 1 abrogated binding of anti-C3 to sensitized cells in incubation 2. When incubation 1 was carried out in the presence of 50 mM EDTA, binding was reduced by 95 and 91%, respectively.
The temperature dependence of complement activation and the effect of complement inactivation during incubation 1 on subsequent anti-C3 binding during incubation 2 strongly support the contention the C3 is being fixed to the surface of PFG. Immune complexes, which did not bind to granulocytes but caused fluid-phase complement activation in the assay, could explain the observed ability of FS sera to activate complement and fix increased amounts of C3 However, when granulocytes were incubated with test serum and washed before the addition of fresh normal serum as the complement source and completion of the standard assay, FS serum bound 48.4 fg anti-C3 (with the extra wash step), as compared with 48.6 fg anti-C3 (using the standard assay).
IgG antibody or immune complexes bound to granulocyte Fc receptors might activate complement and fix C3 to the surface of granulocytes. We investigated whether complement activation was occurring by nonspecific IgG binding to Fc receptors by examining binding of anti-C3 after incubation of cells with a frpsh complement source and the sera of two patients with multiple myeloma. Both these patients had a monoclonal gammopathy by serum electrophoresis with elevated amounts of "M" protein of the IgG, type as established by immunoelectrophoresis against specific antigamma immunoglobulins. Granulocytes incubated with these two sera in the presence of a complement source bound only. 10.7 and 7.0 fg anti-C3 per cell, respectively. Furthermore, granulocytes incubated with these sera bound 0.01 and 0.07 fg SPA, respectively, indicating that the amount of IgG bound to granulocytes by FS sera was in excess of that which could be accounted for by Fc FELTY'S SYNDROME n-13 FIGURE 6 CS fixation by sera from control subjects, patients with RA, and patients with FS. The results are expressed as in Fig. 2 (Fig. 7) . Aliquots of selected serum fractions were used without further adjustment of concentration in the standard anti-CS binding assay. The peak of complement activating ability coincided with the monomeric IgG-containing fractions of FS serum, represented by the second protein peak. (Fig. 8) . For 10 patients with RA, the distribution of values fell within the range of controls. Results from patients with RA were clustered together in the region of low amounts of granulocyte-binding IgG and low amounts of C3 fixation. In contrast, both of these parameters were elevated in most FS patients.
Although the values were spread over a large range, increased amounts of granulocyte-binding IgG were positively correlated with an increased ability of FS sera to fix C3 to granulocytes (r = 0.6).
DISCUSSION
The role of complement in modulating the immune destruction of erythrocytes and platelets and the similarity in clinical expression of immune granulocytopenia to immune hemolytic anemia and immune thrombocytopenia suggest a potential role for complement activation in immune granulocytopenia (1). Some antigranulocyte antibody assays detect complement-mediated granulocytotoxicity. Drew and coworkers (18) have developed an antibody-dependent, complement-mediated microgranulocytotoxicity assay, which has found wide application in the screening (25) . Using the '251-labeled anti-C3 antibody (anti-C3) binding assay, we found major differences in the ability of sera from patients with FS to fix C3 to granulocytes, as compared with sera from patients with uncomplicated RA and control subjects. Although the C3-fixing activity of sera from patients with RA was indistinguishable from that of normal subjects, sera from 7 of 13 patients with FS had increased C3-fixing capabilities. In these patients, two to three times as much anti-C3 was bound per cell as in patients with RA. The effects of alterations in temperature and of complement inhibition during the incubation of cells with serum in the presence of a complement source support the conclusion that C3 was being fixed to granulocytes by the activation of complement.
The ability of FS serum to activate complement and fix C3 to granulocytes may be derived from the presence of immune complexes. Hurd et al. (26) (27) . By interposing a wash step between the time when cells were incubated with FS serum and the time when a fresh complement source was added, we were able to determine whether the anti-C3 binding detected in our assay was due to fixation of C3 to granulocytes after fluid-phase activation had occurred. The complement-activating principle in test serum bound to cells and persisted after washing. In addition, incubation of granulocytes with heat-aggregated IgG, and fresh normal serum did not cause augmented anti-C3 binding despite an increase in the amount of granulocyte-bound IgG. This finding diminished the possibility that bound immune complexes were responsible for significant levels of complement activation in our assay system. To further define the immunoglobulin species involved, binding of anti-C3 was measured following incubation of granulocytes and a fresh complement source with fractionated FS serum. Virtually all of the C3-fixing activity resided in the monomeric IgG-containing fraction, whereas no C3 was fixed by the fractions containing pentameric IgM or high-molecular weight immune complexes.
Although autoantibodies to a granulocyte-specific antigen have been described in a patient with idiopathic autoimmune granulocytopenia (28) To allow isolation of the surface-related events from intracellular metabolic activity in the anti-C3 binding assay, we used fixed cell surfaces as the target for activation of complement. Paraformaldehyde fixation of granulocytes has been shown to preserve potential antigen-binding sites for serum antigranulocyte antibody and to preserve granulocyte-bound IgG (8, 15, 31, 32) . This fixation procedure apparently does not disturb the cell surface configuration that is receptive to binding to C3b in nonfixed target cell systems (33) , as demonstrated by our ability to detect C3 fixation by binding of anti-C3 to sensitized PFG. Importantly, <2% of anti-C3 binding to unsensitized PFG was a result of nonspecific adsorption of anti-C3, such as to Fc receptors, and PFG by themselves did not activate complement to an appreciable extent in the absence of FS sera.
We investigated the contribution of bound antigranulocyte antibody to the complement-activating ability of FS sera by the concurrent measurement of SPA binding and anti-C3 binding. No serum caused increased complement activation without elevated granulocyte-binding IgG. The antigens involved in the binding of antigranulocyte antibody must therefore be densely distributed on the granulocyte surface since fixation of Clq requires a pair of closely apposed IgG molecules (34) . In contrast, pentameric IgM antibody may not require proximity of antigens to activate complement. Six patients with FS had elevated granulocyte-binding IgG without increased fixation of C3. These patients may have had antibodies directed against sparsely distributed antigens, as has been found in the lack of complement fixation by anti-Rh IgG (35) or may possibly have had granulocyte-binding IgG of subclasses that do not react efficiently with Clq, such as IgG2 or IgG4 (36), both of which bind SPA (37) . Alternatively, such patients may have pathophysiologically less important levels of antigranulocyte antibody and perhaps have suppressor T-cell mediated granulocytopenia (6) .
The amount of C3 fixed to granulocytes and the amount of IgG bound were elevated in 7 of 13 patients with FS, but the amount of C3 fixed was proportional to the amount of IgG bound in the entire group. In concert with the results of our other experiments, this correlation is strong evidence that the granulocytebinding IgG present in the sera of patients with FS activates complement and fixes C3 to the surface of granulocytes when bound to antigens on the granulocyte surface. The fixation of C3 by granulocyte-binding IgG may prove to be critical in our understanding of the pathophysiology of granulocytopenia in FS, as well as in the other clinical syndromes of immune granulocytopenia, including perhaps drug-induced granulocytopenia (38) , by virtue of the opsonizing and chemotactic properties of the C3 oligopeptides.
